https://www.selleckchem.com/pr....oducts/pqr309-bimira
15) or without diabetes (ATHENA 741 vs 492days, log-rank p0.0001; EURIDIS/ADONIS 120 vs 59days, log-rank p=0.0002). Occurrence of any treatment-related adverse events with dronedarone was similar for patients with/without diabetes and was comparable to placebo. Dronedarone reduced incidence of CV hospitalization/death, AF/AFL recurrence and increased time to these events in AF/AFL patients with/without diabetes. Not applicable, as it was a post hoc analysis. This article is based on previously conducted studies (ATHENA NC
Like
Comment
Share
